{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-24-000016","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.865082+00:00","generated_at":"2026-06-02T05:06:44.178878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune reports Q1 2024 net loss $24.4M; cash $182.1M; pemvidutide milestones on track","bullets":["Net loss $24.4M ($0.34/share) vs $20.1M ($0.40) in Q1 2023; R&D expense $21.5M on pemvidutide and HepTcell winddown.","Cash, equivalents & short-term investments $182.1M as of March 31, 2024.","Phase 2b MASH trial (IMPACT) enrollment ongoing; top-line results expected Q1 2025.","End-of-Phase 2 FDA meeting for pemvidutide obesity program expected late Q3 2024.","MOMENTUM Phase 2 data showed 74.5% weight loss from fat, 25.5% from lean mass; visceral fat preferentially reduced."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-24-000016","json":"https://secwatch.observer/filing/0001326190-24-000016.json","markdown":"https://secwatch.observer/filing/0001326190-24-000016.md","text":"https://secwatch.observer/filing/0001326190-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/0001326190-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/alt-20240509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:06:44.178878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35f030d85a3cca59ae1a13a5d419c634a665ab4f","claim":"Altimmune, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, EPS $0.34 net loss per share.","evidence_excerpt":"● Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, compared to a net loss of $20.1 million, or $0.40 net loss per share, in the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/0001326190-24-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share"},{"label":"EPS","value":"$0.34 net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}